Analyst Price Target is $46.25
▲ +67.94% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Tarsus Pharmaceuticals in the last 3 months. The average price target is $46.25, with a high forecast of $65.00 and a low forecast of $33.00. The average price target represents a 67.94% upside from the last price of $27.54.
Current Consensus is
The current consensus among 5 polled investment analysts is to buy stock in Tarsus Pharmaceuticals.
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.